anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methotrexate (MTX) is an effective treatment for induction of remission and maintenance in patients with Crohn's disease, rheumatoid arthritis, or psoriasis which may induce liver fibrosis with high cumulative doses. Transient elastography (FibroScan) is a new non-invasive rapid, reproducible and bed-side method, allowing assessment of liver fibrosis by measurement of liver stiffness. A preliminary study (Laharie et al, Alimentary Pharmaceutical Therapeutics 2006) had shown that significant liver fibrosis was rare in Crohn's disease patients treated with a high dose of methotrexate. FibroScan was a reliable non-invasive method to detect liver fibrosis which could be recommended in these patients. Therefore, liver biopsy could be performed only with patients with high FibroScan values and/or with chronic liver enzymes abnormalities. However, further longitudinal and prospective studies are mandatory to confirm these preliminary data, in patients with crohn's disease but also with rheumatoid arthritis and psoriasis.
Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
The goal of this K01 application is to develop and pilot test an individually tailored, pre-visit health communication intervention targeting HPV-VH parents. The partnering clinic is Meharry Medical College Pediatric Group (MMC Pediatrics), a safety-net clinic serving primarily publicly-insured and uninsured patients. The study has three specific aims.

Aim 1. To develop a tailored, health communication intervention targeting HPV-VH parents prior to clinic visits. The tailored intervention will be delivered to VH parents via mobile phones. Investigators will draft initial content based on the Theory of Reasoned Action and Health Belief Model, previous VH research,14 and preliminary data. Then semi-structured interviews will be conducted with 25-30 VH parents who previously declined the HPV vaccine and 10 physicians to elicit feedback on draft content. Qualitative data will be collected and analyzed iteratively, informing successive modifications to the intervention to cover a range of potential concerns for VH parents, enhance message relevance, and refine the intervention delivery process. Next, investigators will work with MMC Pediatrics to develop and refine the study protocol. Investigators will pre-test and get feedback on the protocol from 16 VH parents and 3 physicians to maximize acceptance and feasibility.

Aim 2. Conduct a pilot study of the intervention and study protocol to demonstrate feasibility for the future full-scale randomized control trial (RCT). Based on Aim 1, investigators will conduct a small, pilot RCT with 70 VH parents with scheduled clinic visits. Feasibility indicators are recruitment rates, retention rates, and ability to ascertain patients' post-visit HPV vaccine status in the clinical record. VHealth software will be used to extract information from the EHR to identify potentially eligible patients with a previous HPV vaccine refusal and to determine the whether an HPV vaccine dose was received during the scheduled visit.

Aim 3. Examine acceptability of the intervention and protocol among parents and providers. Parents participating in the pilot study will complete a post-visit survey to measure acceptability of the intervention and protocol, provider trust/rapport, and satisfaction with provider-patient communication. In addition, investigators will conduct semi-structured debriefing interviews with a subset of 20-30 parents and 3 providers to gather qualitative data about their experiences (e.g., unforeseen problems and barriers) and their perceptions of acceptability of the intervention and protocol (e.g., ease of use, content, graphics). The findings will be used identify needs for any additional modifications to the intervention and protocol prior to the RCT.
<P>PROBLEM TO BE SOLVED: To provide systems and methods for monitoring characteristics of a subject.  <P>SOLUTION: The system has a sensor subsystem and a processor subsystem under a communication condition with the sensor subsystem. The sensor subsystem has at least one respiratory sensor disposed proximate to the subject and configured to detect a respiratory characteristic of the subject and at least one of physiological sensor disposed proximate to the subject and configured to detect the physiological characteristic of the subject. The sensor subsystem is configured to generate and transmit at least one respiratory signal showing the respiratory characteristic and is configured to generate and transmit at least one physiological signal showing the physiological characteristic. The processor subsystem is configured to receive at least one of the at least one of respiratory signal and the at least one of physiological signal.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The present invention relates to a traditional Chinese medicine preparation for treating sexual disorders, menoxenia and barrenness and for increasing immunological functions. The present invention has an edible function and a medical function, which is prepared by adding malt sugar in nine kinds of Chinese herbal medicine, such as ladybell root, prepared fleece-flower root, dodder, Chinese pyrola herb, tuckahoe, malaytea scurfpea fruit, Chinese angelica, Chinese wolfberry and antler glue. The commercial name of the present invention is determined as Chinese pyrola herb. Used as a traditional Chinese medicine preparation and a health-care product, the present invention is used for treating stubborn disease symptoms, such as male sexual disorders, female menoxenia, long-time barrenness, etc. The present invention has quick therapeutic effect on improving male sexual disorders, has good therapeutic effect for male oligospermatism, and has obvious effect on improving symptoms, such as female frigidity, paramenia, sanguinous leukorrhea, etc. The preparation has exact therapeutic effect. After taken, the present invention can increase organismal resistance for the diseases, can quickly relieve symptoms, and has obvious therapeutic effect and health-care effect on refection, etc. after operation, chemotherapy and radiotherapy for a patient with cancer. Because the present invention is a pure natural plant preparation, the present invention has the advantages of sufficient raw material source, simple and easy preparing technology, and low production cost.
FIELD: pharmacy. SUBSTANCE: invention relates to a new oral pharmaceutical preparation consisting of at least 50 individual particles, their size is from 0.2 to 3 mm. Each particle including a morphine salt-containing corn is covered by protective layer providing the controlled, preferably pH-independent morphine release. To obtain the new morphine preparation particles are subjected for covering process in fluidized layer using covering liquid as a solution, dispersion, suspension or emulsion. Preparation is used for anesthetization and relieve of severe chronic pains exhibiting sensitivity to opioids. Preparation is given once per a day that provides the significant decrease of morphine concentration fluctuation in blood plasma as compared with its the known preparations. EFFECT: improved quality and properties of the preparation. 15 cl, 1 dwg, 10 tbl, 3 ex
Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
Human experience of acute overdose with zileuton is limited. A patient in a clinical trial took between 6.6 and 9.0 grams of zileuton in a single dose. Vomiting was induced and the patient recovered without sequelae. Zileuton is not removed by dialysis. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted as required. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. A Certified Poison Control Center should be consulted for up-to-date information on management of overdose with ZYFLO. 

The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively). No deaths occurred, but nephritis was reported in dogs at an oral dose of 1000 mg/kg (providing in excess of 12 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose).
The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer. In some embodiments, the compound can comprise amorphous networks. In some embodiments, the compound can include semi-crystalline networks.
The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
A data processing system is configured to identify treatment responsive to a health risk determined from feature data provided by one or more networked data sources. A classification engine generates a feature vector based on a natural language processing (NLP) of input data representing words provided by a user. Features of the feature vector represent health risk factors. Machine learning logic classifies the features to generate a classification metric indicating whether the features are indicative of health risks or not indicative of health risks. A prediction value is generated indicating a likelihood of each health risk factor for the patient. The patient can be diagnosed with a health condition or disease based on the identified health risks.
Patients receive \^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second \^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior \^18F FDG PET scan as part of their routine clinical management undergo \^18F FDG PET scanning at baseline.
During the NSCLC and the combination pancreatic cancer trials, infrequent cases of gastrointestinal bleeding have been reported, some associated with concomitant warfarin or NSAID administration. [see Warnings and Precautions (5.9)]. These adverse events were reported as peptic ulcer bleeding (gastritis, gastroduodenal ulcers), hematemesis, hematochezia, melena and hemorrhage from possible colitis. Cases of acute renal failure or renal insufficiency, including fatalities, with or without hypokalemia have been reported. [see Warnings and Precautions (5.4)].  Cases of Grade 1 epistaxis were also reported in both the single-agent NSCLC and the pancreatic cancer clinical trials.

NCI-CTC Grade 3 conjunctivitis and keratitis have been reported infrequently in patients receiving TARCEVA therapy in the NSCLC and pancreatic cancer clinical trials. Corneal ulcerations may also occur. [see Patient Counseling Information (17)].

Hair and nail disorders including alopecia, hirsutism, eyelash/eyebrow changes, paronychia and brittle and loose nails have been reported in clinical trials and during post-marketing use of TARCEVA.

In patients who develop skin rash, the appearance of the rash is typically erythematous and maculopapular and it may resemble acne with follicular pustules, but is histopathologically different. This skin reaction commonly occurs on the face, upper chest and back, but may be more generalized or severe (NCI-CTC Grade 3 or 4) with desquamation. Associated symptoms may include itching, tenderness and/or burning. Dry skin with or without digital skin fissures may occur. 

Hepatic failure has been reported in patients treated with single-agent TARCEVA or TARCEVA combined with chemotherapy in clinical studies and during post-marketing use of TARCEVA [see Warnings and Precautions (5.3 )]; it is not possible to reliably estimate the frequency or establish a causal relationship to TARCEVA treatment.

In general, no notable differences in the safety of TARCEVA monotherapy or in combination with gemcitabine could be discerned between females or males and between patients younger or older than the age of 65 years [see Use in Specific Populations (8.4)]. The safety of TARCEVA appears similar in Caucasian and Asian patients.
PCT No. PCT/US94/04838 Sec. 371 Date Oct. 26, 1995 Sec. 102(e) Date Oct. 26, 1995 PCT Filed Apr. 29, 1994 PCT Pub. No. WO94/25626 PCT Pub. Date Nov. 10, 1994Methods for determining the genotoxic or carcinogenic status of a subject by analyzing the cellular redox potential of a test specimen where an increased risk of, or presence of, genotoxic injury or cancer is indicated when the cellular redox potential favors oxidatively derived modified nucleotide bases. A sensitive method is disclosed wherein DNA is isolated from a test specimen obtained from a test subject and assayed for modified nucleotide bases that have formed either stable reductively formed derivatives or stable oxidatively formed derivatives. By identifying and comparing those modified nucleotide bases derived via reductive pathways to those modified nucleotide bases derived via oxidative patwhays, a determination as to the cancer status of the test specimen can be made wherein a greater cancerous state exists when the ratio between the two species of modified nucleotide bases indicates that oxidatively formed derivative are favored over reductively formed derivatives. Also disclosed are methods for modulating the cellular redox potential so as to decrease the likelihood of oxidatively derived modified base formation and cancer formation. Methods for monitoring the efficacy of such therapy are additionally disclosed.
The invention discloses a traditional Chinese medicine composition for treating night sweat, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15-25 parts of radix astragali, 8-12 parts of radix rehmanniae recen, 10-12 parts of rhizoma anemarrhenae, 15-25 parts of radix sophorae flavescentis, 20-30 parts of ossa draconis, and 20-30 parts of oyster. A preparation method comprises the steps: putting the raw materials into a drug decocting pot, adding water to cover the raw material medicines, boiling with big fire, then decocting for 30-60 minutes with small fire, pouring out a medicinal liquid, then adding water, decocting for 30-60 minutes, pouring out a medicinal liquid, and mixing the two medicinal liquids. A taking method comprises the steps: taking the medicine for one time each in the morning and in the evening, and taking after meals. The radix astragali is capable of invigorating spleen-stomach and replenishing qi, relieving sweat, and promoting urination and eliminating swelling. The radix rehmanniae recen is capable of removing heat to cool blood, and nourishing yin and generating body fluid. The rhizoma anemarrhenae is capable of clearing heat to decrease internal heat, and nourishing yin and moistening dryness. The radix sophorae flavescentis is capable of clearing away heat and drying dampness, killing pests and promoting diuresis. The ossa draconis is capable of astringing qi to remove dampness, and stopping night sweat. The oyster is capable of retaining yin with astringent and restraining hyperactivity of yang, and relieving sweat and arresting seminal emission. The traditional Chinese medicine composition has obvious curative effect on night sweat. Moreover, the preparation is simple, and the raw materials are easy to obtain.
Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
Intracranial high-density electrodes make it possible to record neural activity directly from the brain surface with unparalleled spatial and temporal resolution to unravel both local and population encoding of speech sounds. This study proposes to assess speech perception in patients who are undergoing surgery for seizure localization or awake intraoperative brain mapping. Electrode placement is based on the clinical needs of each patient. The research study team will examine the mechanisms of phonetic encoding to reveal both the organization of auditory speech feature selectivity and the distributed population-level processing that give rise to the emergent properties of spoken language perception. The aims of this study seeks to determine the cortical encoding of phonological sequencing (Aim 1), representation of amplitude landmark coding in speech (Aim 2), and the shared and distinct mechanisms for speech and music melody encoding (Aim 3). Together, these aims will advance our understanding of speech encoding in the human brain beyond consonants and vowels, addressing questions pertaining to sequencing, amplitude coding, and auditory specialization. These results should heavily impact current theories of speech processing and, therefore, will have significant implications for understanding and remediating human language disorders.
The project draws on our strong findings from the preliminary work we conducted in the US (R34 pilot randomized control trial \& mixed method acceptability project). The 5-year project will revise and update an existing digital health couples-based HIV/STI prevention toolkit intervention that showed promise for reducing couples' HIV risk. The intervention is theoretically grounded in Couples Interdependence Theory for health behavior change. The project is a 16-month randomized control trial with 375 at-risk male couples using a delayed, educational control condition of 8 months. Our Specific Aims are to: 1) examine efficacy of the intervention on couples' a) formation and adherence to a risk-reduction plan and agreement, b) relationship functioning, c) self-reported and biomarker-confirmed indicators of risk (sexual behavior and STI), and engagement in HIV prevention (PrEP adherence) and care (ART adherence); 2) evaluate use of the intervention over time by using three different data sources; 3) explore moderating and mediating effects on couples' outcomes a-c. The project has high Public Health significance given the HIV disparities and the importance of attending to couples' unique relationship and prevention needs.
<P>PROBLEM TO BE SOLVED: To provide an artificial pumice filled with a metabolism accelerator such as salt, an antibacterial agent or a perfume.  <P>SOLUTION: By mixing a microencapsulated perfume 1 into a hard synthetic resin foam 10 such as a polyurethane, the releasing effect of the metabolism accelerator or the perfume can be expected. Furthermore, even if the perfume is volatile, since the microcapsule does not release a scent until it gets broken, the perfume is very sustainable. A salt or other metabolism accelerator 2 may be added when required. Such an artificial pumice has also aromatic, perspiratory and antibacterial functions in addition to a keratin removal function.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
FIELD: medicine, virology. SUBSTANCE: method ensures to inactivate an infectious activity of virus at low concentrations of reagent but retains antigenicity and immunogenicity of viral proteins and viability of human and animal cell cultures. Method involves the treatment of virus-containing suspension of human or animal cultures with ethanol followed by incubation of the mixture at the room temperature. Invention can be used for inactivation of human immunodeficiency virus-1 in biological materials. EFFECT: enhanced effectiveness of virus inhibition. 3 cl, 5 tbl, 5 ex
The invention is related to recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited in the ECCC 97061101 according to the Budapest Treaty. These recombinant antibodies were obtained by recombinant DNA technology, and recognised an antigen called IOR C2. The recombinant antibodies are the chimeric and humanised antibodies, and the single chain Fv. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanised antibody contains the human constant regions and it has been modified its murine frameworks (FRs) specifically into a possible antigenic site for humanising T-cell epitopes. The Fv fragment contains the variable murine domains. This invention is also related with the use of recombinant antibodies from murine IOR C5 for the diagnosis and therapy of colorectal tumours, its metastasis and recidives.
Elevated lipoprotein(a) is a genetically transmitted codominant trait that is an independent risk driver for cardiovascular disease. Lipoprotein(a) concentration is heavily influenced by genetic factors, including LPA kringle IV-2 domain size, single-nucleotide polymorphisms, and interleukin-1 genotypes. Apolipoprotein(a) is encoded by the LPA gene and contains 10 subtypes with a variable number of copies of kringle -2, resulting in >40 different apolipoprotein(a) isoform sizes. Genetic loci beyond LPA, such as APOE and APOH, have been shown to impact lipoprotein(a) levels. Lipoprotein(a) concentrations are generally 5% to 10% higher in women than men, and there is up to a 3-fold difference in median lipoprotein(a) concentrations between racial and ethnic populations. Nongenetic factors, including menopause, diet, and renal function, may also impact lipoprotein(a) concentration. Lipoprotein(a) levels are also influenced by inflammation since the LPA promoter contains an interleukin-6 response element; interleukin-6 released during the inflammatory response results in transient increases in plasma lipoprotein(a) levels. Screening can identify elevated lipoprotein(a) levels and facilitate intensive risk factor management. Several investigational, RNA-targeted agents have shown promising lipoprotein(a)-lowering effects in clinical studies, and large-scale lipoprotein(a) testing will be fundamental to identifying eligible patients should these agents become available. Lipoprotein(a) testing requires routine, nonfasting blood draws, making it convenient for patients. Herein, we discuss the genetic determinants of lipoprotein(a) levels, explore the pathophysiological mechanisms underlying the association between lipoprotein(a) and cardiovascular disease, and provide practical guidance for lipoprotein(a) testing.
Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.